ELMMB logo
Facebook logo Twitter logo
MHRA Drug Safety Updates

MHRA Drug Safety Updates

MHRA Yellow Card Scheme: please help to reverse the decline in reporting of suspected adverse drug reactions 

Items In This Category

application/pdfDrug Safety Update MHRA July 2019 PDF.pdf (398KB)18/07/2019Download
 Febuxostat (Adenuric): increased risk of cardiovascular death and all-cause mortality in clinical trial in patients with a history of major cardiovascular disease. Tocilizumab (RoActemra): rare risk... 
application/pdfDrug Safety Update MHRA June 2019 PDF.pdf (274KB)20/06/2019Download
 Direct-acting oral anticoagulants (DOACs): increased risk of recurrent thrombotic events in patients with antiphospholipid syndrome . GLP-1 receptor agonists: reports of diabetic ketoacidosis when... 
application/pdfDrug Safety Update MHRA May 2019 .pdf (512KB)22/05/2019Download
 Lemtrada (alemtuzumab) and serious cardiovascular and immune-mediated adverse reactions, Tofacitinib (Xeljanz▼): restriction of 10 mg twice-daily dose in patients at high risk of pulmonary embolism... 
application/pdfDrug Safety Update MHRA April 2019 PDF final.pdf (304KB)25/04/2019Download
 Yellow, fever, stamaril, valproate, belimumab, benlysta, lyrica, pregabalin, gabapentin, elvitegravir 
application/pdfDrug Safety Update MHRA March 2019 PDF-final.pdf (388KB)25/03/2019Download
 Fluoroquinolone antibiotics: new restrictions and precautions for use due to very rare reports of disabling and potentially long-lasting or irreversible side effects. Onivyde (irinotecan, liposomal... 
application/pdfDrug safety Update MHRA February 2019.pdf (219KB)18/02/2019Download
 Carbimazole: increased risk of congenital malformations; strengthened advice on contraception. Carbimazole: increased risk of Pancreatitis. SGLT2 inhibitors: reports of Fournier's gangrene. 
application/pdfDrug Safety Update MHRA January 2019.pdf (366KB)11/01/2019Download
 Tapentadol: risk of seizures & reports of serotonin syndrome when co-administered with other medicines.Ipilimumab: reports of cytomegalovirus GU infection or reactivation. 
application/pdfDrug Safety Update MHRA December 2018.pdf (262KB)19/12/2018Download
 Oral lidocaine-containing products for infant teething. Emollients: new information about risk of severe and fatal burns with paraffin-containing and paraffin-free emollients. Direct-acting... 
application/pdfDrug Safety Update MHRA November 2018.pdf (348KB)14/11/2018Download
 Latest advice for medicines users 
application/pdfDrug safety Update October 2018 PDF.pdf (243KB)11/10/2018Download
 Rivaroxaban (Xarelto▼) after transcatheter aortic valve replacement: increase in all-cause mortality, thromboembolic and bleeding events in patients in a clinical trial.Ritonavir-containing products:... 
application/pdfMHRA DSU September 2018 PDF.pdf (267KB)25/09/2018Download
 Valproate Pregnancy Prevention Programme: actions required now from GPs, specialists, and dispensers. Xofigo▼ (radium-223-dichloride): new restrictions on use due to increased risk of fracture and... 
application/pdfDrug Safety Update MHRA Aug 2018.pdf (186KB)28/08/2018Download
 Esmya (ulipristal acetate) and risk of serious liver injury: new restrictions to use and requirements for liver function monitoring before, during, and after treatment 
Page: [1] [2] [3] [4] [5] [6]